Molecular changes and drug therapy

Molecular changes and drug therapy

An increasingly common reason for molecular testing and related immunohistochemistry is the prediction of the response of advanced malignant tumours to specific drugs whose target is usually known (‘theranostics’). For example, tumours with tyrosine kinase gene fusions that result in activation of the kinase are more likely than their counterparts to respond to tyrosine kinase inhibitors. A newer class of drugs known collectively as immune checkpoint inhibitors (ICIs) is highly successful for the treatment of a variety of advanced malignancies. Detection of any of several biomarkers may predict responsiveness to ICIs.

Molecular changes and drug therapy

An increasingly common reason for molecular testing and related immunohistochemistry is the prediction of the response of advanced malignant tumours to specific drugs whose target is usually known (‘theranostics’). For example, tumours with tyrosine kinase gene fusions that result in activation of the kinase are more likely than their counterparts to respond to tyrosine kinase inhibitors. A newer class of drugs known collectively as immune checkpoint inhibitors (ICIs) is highly successful for the treatment of a variety of advanced malignancies. Detection of any of several biomarkers may predict responsiveness to ICIs.

Molecular changes and drug therapy

An increasingly common reason for molecular testing and related immunohistochemistry is the prediction of the response of advanced malignant tumours to specific drugs whose target is usually known (‘theranostics’). For example, tumours with tyrosine kinase gene fusions that result in activation of the kinase are more likely than their counterparts to respond to tyrosine kinase inhibitors. A newer class of drugs known collectively as immune checkpoint inhibitors (ICIs) is highly successful for the treatment of a variety of advanced malignancies. Detection of any of several biomarkers may predict responsiveness to ICIs.